" class="no-js "lang="en-US"> Lotus Mallbris - Medtech Alert
Monday, August 18, 2025
Lotus Mallbris

Lotus Mallbris

About Lotus Mallbris

Passionate, experienced executive leader with inclusive mindset and diverse experience of academic research, pharmaceutical, drug development and global medical affairs. Demonstrated effectiveness in defining a strategic vision, aligning team members to shared values and purpose for success, and energizing team members to execute with integrity and deliver with speed. Believes in continuous improvement and best practice, while able to maintaining high standards with a focus on transforming outcome, execution and delivery. Cross-functional leadership experience in multiple countries. Committed to empowering and developing individuals and teams to improve while taking accountability,

Led collaborating with discovery, preclinical, business development, new product planning, commercial, regulatory and other key functions as well as KOLs, to identify the right indication and patient population, and to design a clinical program from proof of concept to pivotal study with purpose. Worked to file the IND, write the protocol, conduct the study, submission, interaction with FDA including Advisory Committee and other regulatory authorities to gain agreement on endpoints and/or trial design for a registration pathway. NDA/BLA experience. Experience obtaining accelerated approval pathways including Breakthrough Designation, Fast Track status and Orphan Designation. Successful proven track record of developing and executing launch strategy.

• High performance + High integrity
• Strategic life cycle planning
• Regulatory product negotiations and approval
• Global Medical affair and Launch strategy
• Clinical development strategy
• External stakeholder/partnership strategy
• Communication strategy
• Inclusive and transformational leadership

Related Story

Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

April 12 2022

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined […]